Beyond Injections: How Oral GLP-1s Will Fit into Obesity Care This edition covers: The newest oral GLP-1s on the market Clinical differences between oral and injectable GLP-1s How a growing range of options is re-shaping health benefit strategies Last week, the FDA approved Lillys new oral GLP-1 medication, Foundayo (orforglipron), several months after the approval of Novo Nordisks Wegovy (semaglutide) pill the first oral GLP1 indicated both for weight management and for reducing cardiovascular risk in adults with obesity or overweight, and established heart disease
The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs
Neurological health and cognitive function Heart health results from trials suggest that taking vitamin B12 and folic acid reduce homocysteine levels, an amino acid found to be an independent risk factor for cardiovascular disease
The therapeutic role of GLP-1RAs is extending from glucose lowering alone to a broader, multi-organ intervention
The treatment options for c-section pouch and diastasis recti are also different
The results of the subgroup analysis in this study were similar
.jpeg)
